Liraglutide, a long-acting GLP-1 receptor agonist, is widely used for treating diabetes by stimulating glucose-dependent insulin secretion and suppressing glucagon secretion with a very low risk for hypoglycemia [19, 31, 32]. The gene discussed is GLP1R; the disease is Hypoglycemia.